Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.

<h4>Background</h4>The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfizer (BNT162b2) vaccine to preven...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Delphina Gomes, Andreas Beyerlein, Katharina Katz, Gabriele Hoelscher, Uta Nennstiel, Bernhard Liebl, Klaus Überla, Rüdiger von Kries
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/de9ecba25d754328ba676c3a14796db2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de9ecba25d754328ba676c3a14796db2
record_format	dspace
spelling	oai:doaj.org-article:de9ecba25d754328ba676c3a14796db22021-12-02T20:16:24ZIs the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.1932-620310.1371/journal.pone.0259370https://doaj.org/article/de9ecba25d754328ba676c3a14796db22021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0259370https://doaj.org/toc/1932-6203<h4>Background</h4>The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfizer (BNT162b2) vaccine to prevent SARS-CoV-2 infection and severe outcomes in octo- and novo-generians in a German state setting.<h4>Methods and findings</h4>A prospective observational study of 708,187 persons aged ≥80 years living in Bavaria, Germany, was conducted between Jan 9 to Apr 11, 2021. We assessed the vaccine effectiveness (VE) for two doses of the BNT162b2 vaccine with respect to SARS-CoV-2 infection and related hospitalisations and mortality. Additionally, differences in VE by age groups ≥80 to ≤89 years and ≥90 years were studied. Analyses were adjusted by sex. By the end of follow-up, 63.8% of the Bavarian population ≥80 years had received one dose, and 52.7% two doses, of the BNT162b2 vaccine. Two doses of the BNT162b2 vaccine lowered the proportion of SARS-CoV-2 infections and related outcomes, resulting in VE estimates of 68.3% (95% confidence interval (CI) 65.5%, 70.9%) for infection, 73.2% (95% CI 65.3%, 79.3%) for hospitalisation, and 85.1% (95% CI 80.0%, 89.0%) for mortality. Sex differences in the risk of COVID-19 outcomes observed among unvaccinated persons disappeared after two BNT162b2 vaccine doses. Overall, the BNT162b2 vaccine was equally effective in octo- and novo-genarians.<h4>Conclusions</h4>Two doses of BioNTech-Pfizer's BNT162b2 vaccine is highly effective against COVID-19 outcomes in elderly persons.Delphina GomesAndreas BeyerleinKatharina KatzGabriele HoelscherUta NennstielBernhard LieblKlaus ÜberlaRüdiger von KriesPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11, p e0259370 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Delphina Gomes Andreas Beyerlein Katharina Katz Gabriele Hoelscher Uta Nennstiel Bernhard Liebl Klaus Überla Rüdiger von Kries Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
description	<h4>Background</h4>The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfizer (BNT162b2) vaccine to prevent SARS-CoV-2 infection and severe outcomes in octo- and novo-generians in a German state setting.<h4>Methods and findings</h4>A prospective observational study of 708,187 persons aged ≥80 years living in Bavaria, Germany, was conducted between Jan 9 to Apr 11, 2021. We assessed the vaccine effectiveness (VE) for two doses of the BNT162b2 vaccine with respect to SARS-CoV-2 infection and related hospitalisations and mortality. Additionally, differences in VE by age groups ≥80 to ≤89 years and ≥90 years were studied. Analyses were adjusted by sex. By the end of follow-up, 63.8% of the Bavarian population ≥80 years had received one dose, and 52.7% two doses, of the BNT162b2 vaccine. Two doses of the BNT162b2 vaccine lowered the proportion of SARS-CoV-2 infections and related outcomes, resulting in VE estimates of 68.3% (95% confidence interval (CI) 65.5%, 70.9%) for infection, 73.2% (95% CI 65.3%, 79.3%) for hospitalisation, and 85.1% (95% CI 80.0%, 89.0%) for mortality. Sex differences in the risk of COVID-19 outcomes observed among unvaccinated persons disappeared after two BNT162b2 vaccine doses. Overall, the BNT162b2 vaccine was equally effective in octo- and novo-genarians.<h4>Conclusions</h4>Two doses of BioNTech-Pfizer's BNT162b2 vaccine is highly effective against COVID-19 outcomes in elderly persons.
format	article
author	Delphina Gomes Andreas Beyerlein Katharina Katz Gabriele Hoelscher Uta Nennstiel Bernhard Liebl Klaus Überla Rüdiger von Kries
author_facet	Delphina Gomes Andreas Beyerlein Katharina Katz Gabriele Hoelscher Uta Nennstiel Bernhard Liebl Klaus Überla Rüdiger von Kries
author_sort	Delphina Gomes
title	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
title_short	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
title_full	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
title_fullStr	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
title_full_unstemmed	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
title_sort	is the bnt162b2 covid-19 vaccine effective in elderly populations? results from population data from bavaria, germany.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/de9ecba25d754328ba676c3a14796db2
work_keys_str_mv	AT delphinagomes isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT andreasbeyerlein isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT katharinakatz isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT gabrielehoelscher isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT utanennstiel isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT bernhardliebl isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT klausuberla isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT rudigervonkries isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany
_version_	1718374496058998784

Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.

Ejemplares similares